Main Article Content
This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.
Downloads month by month
Download data is not yet available.
How to Cite
Kinsey-Trotman, S., Shi, Z., & Fosh, B. (2016). Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy. Oncology Reviews, 10(2). https://doi.org/10.4081/oncol.2016.304
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.